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Objectives: To assess the effectiveness, tolerability and maintenance of vildaglip-
tin in type 2 diabetes (T2D) patients under real-life conditions in France, requested 
by the French Health Technology Agency. MethOds: A representative sample of 
T2D patients initiating a treatment with vildagliptin was enrolled in a 2 years fol-
low-up observational cohort in 2010 by a national sample of endocrinologists and 
general practitioners. Results: A total of 482 GPs and 84 endocrinologists included 
1,700 patients. 60% were males, mean age= 63 (±9) years, mean disease duration= 7 
(±6.5) years. Follow up visits were available for 96.3%, 90.7%, 86.5% and 81.8% of 
patients at respectively 6, 12 18 and 24 months. Mean HbA1c level decreased from 
7.8% (sd= 1.3) before vildagliptin prescription to 7.0% (sd= 1.0) 0 to 6 months after 
vildagliptin initiation and remained stable thereafter: 7.0% (sd= 1.0), 7.0% (sd= 0.9) 
and 7.0% (sd= 1.0) 6 to 12 months, 12 to 18 months and 18 to 24 months after vilda-
gliptin initiation. The percentages of patients with alanine and/or aspartate ami-
notransferase above 120 UI were 0.5% before vildagliptin prescription and 0.3%, 0.5%, 
0.1%, 0.0% at 0-6 months, 6-12 months, 12-18 months and 18-24 months after vilda-
gliptin prescription. The mean glomerular filtration rate (MDRD formula) was 82.0 
ml/minute before vildagliptin prescription and 82.4, 84.1, and 83.6 and 82.8, at 0-6 
months, 6-12 months, 12-18 months and 18-24 months after vildagliptin prescrip-
tion. The incidence of severe hypoglycemia (requiring third party assistance) has 
been estimated at 0.30/100 vildagliptin treated patients years (CI95%= [0.15,0.55]). 
All occurred in patients also treated with insulin and/or sulfamide The proportion 
of patients treated with vildagliptin remained high over the course of the study: 
96.5% (CI95%[95.6,97.4]) after 6 months, 92.5% (CI95%= [91.2%,93.8%]) after one year 
and 88.8% (CI95%= [87.2%,90.4%]) after 2 years. cOnclusiOns: Vildagliptin showed 
sustained effectiveness in terms of reduction in HbA1c over 24 months, with a low 
incidence of hypoglycemia.
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Objectives: To compare clinical outcomes and the health care costs across 
two cohorts of uncontrolled diabetic patients who initiated treatment with 
Sulfonamides or Thiazolidinediones (SU/TZD) or Dipeptidyl Peptidase 4 (DPP-4) 
Inhibitors in a clinical practice setting. MethOds: A retrospective analysis using a 
large administrative database and a clinical registry containing laboratory results 
of three Italian Local Health Units was performed. The index-period ranged from 
July, 2008 and June, 2010. Patients were treatment naïve to SU/TZD or to DPP-4, 
but already treated with other oral antidiabetic agents. Demographics, concomi-
tant therapies, Charlson comorbidity index, glycemic and lipid control level and 
previous hospitalizations were assessed at baseline. Adherence was measured 
by Medication Possession Ratio (MPR). We calculated unadjusted rates and used a 
Poisson regression model to estimate risk ratios for diabetes-related hospitaliza-
tions occurred during the 18-months follow-up period. Total annual costs included 
all the pharmacological treatments and the direct costs due to hospitalizations 
and outpatient services. Results: We identified 1384 patients treated with SU/
TZD and 199 treated with DPP-4. DPP-4 patients were significantly younger (mean 
age 59.2 years and 65.0 years; p< 0.001) and with less previous hospital discharges 
for diabetes-related diseases. Baseline mean HbA1c was 8.1% for SU/TZD and 
8.2% for DPP-4 patients. DPP-4 naïve resulted more adherent (MPR≥ 80%) than SU/
TZD naïve (70.9% and 55.8%; p< 0.001). The SU/TZD group showed a significant 
increased risk of diabetes-related hospitalizations (unadjusted rate was 9,17 vs 
3,47 per 100 person-years, p= 0.002; adjusted incidence rate ratio 1.83; p= 0.028). 
The higher hospitalization rate resulted in higher total annual direct costs per 
patient (€ 2.719 vs € 2.462 of those treated with DPP-4). cOnclusiOns: Results 
indicate that uncontrolled diabetic patients who initiated treatment with DPP-4, 
compared with those initiating with SU/TZD, are associated with a reduced risk 
of diabetes-related hospitalizations and consequently with a lower overall total 
annual cost per patient.
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Objectives: To describe epidemiological characteristics among adrenal insufficiency 
(AI) patients and describe the prevalence of risk factors in primary and secondary AI 
(PAI; SAI) and an unmatched, non-AI population. These analyses explore metabolic 
morbidity in AI, which literature suggests may be associated to a non-physiological 
cortisol profile. MethOds: Initial aggregated data from the FARSITE database were 
analysed. The prevalence of risk factors was evaluated, including hypertension, BMI, 
diabetes and depression, and compared across PAI, SAI and non-AI populations. 
Characteristics of non-AI patients were not matched with AI patients. Results: A 
total of 261,638 patients were included; 62 PAI and 191 SAI. Prevalence of hypertension 
was 32% in PAI, 22% in SAI and 13% non-AI. 26% of hypertension in SAI was not on 
target according to QOF criteria (14% non-AI; 10% PAI). Hypercholesterolemia occurred 
in 13% of PAI and 6% of SAI patients (3% non-AI). Among SAI patients, 69% were over-
weight (BMI> 25) or obese (BMI> 30) (63% PAI; 39% non-AI). Diabetes (Type 1 and 2) was 
prevalent in 13% of PAI and 10% of SAI (5% non-AI), with HbA1c not controlled accord-
ing to QOF criteria in 75% of PAI and 74% of SAI patients. Psychological risk factors 
were more prevalent among AI patients; 24% of PAI and 14% of SAI patients recently 
received anti-anxiety/depression treatment (6% non-AI). Hypnotics were recently 
prescribed to 6% of SAI patients (1% non-AI; PAI not reported). Bisphosphonates are 
used by 21% of PAI and 8% of SAI patients (2% non-AI). The hospital admission rate 
was 3% for SAI patients (1% non-AI; PAI not reported). cOnclusiOns: The preva-
lence of metabolic and other risk factors is considerably higher among AI patients 
indirect pairwise odds ratios (OR) were obtained. The study used Bayesian Analysis 
Using Gibbs Sampling in Windows (WinBUGS) version 1.4.3. and Monte Carlo 
Simulations to conduct a multiple treatment comparison. Results are reported in 
OR with 95% credible intervals (CI) and the median of ranking. Results: There were 
a total of 10 studies with 23 treatment arms, representing 2,885 subjects enrolled, 
that were included in the analysis. The results from fix effects model indicated 
that duloxetine, pregabalin, gabapentin, and co-administration of duloxetine and 
gabapentin were significantly better than amitriptyline (OR= 3.22[95%CI, 1.54-7.17], 
OR = 2.53[95%CI, 1.11-5.94], OR = 4.00[95%CI, 1.33-11.69], OR = 2.86[95%CI, 1.09-7.48], 
respectively). The results from random effects model suggested that only duloxetine 
and pregabalin were significantly better than placebo (OR = 2.61[95%CI, 1.37-4.95] 
and OR = 1.97[95%CI, 1.01-3.62], respectively). There was no significant difference 
between amitriptyline and placebo in either fixed or random effects models. With 
regard to the median ranking, gabapentin was ranked first, followed by duloxetine, 
co-administration of duloxetine and gabapentin, pregabalin, placebo, and amitrip-
tyline from the fix effects model. cOnclusiOns: Treatment of PDPN with amitrip-
tyline does not appear to be significantly different from placebo. Duloxetine and 
pregabalin appear to be better than both amitriptyline and placebo.
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Objectives: The GALATA study was the first observational study on DPP-4 inhibitors in 
Turkey and aimed to evaluate the efficacy, safety and tolerability of vildagliptin and met-
formin combination (VMc) in patients with type 2 diabetes mellitus (T2DM). MethOds: 
A total of 648 of the 682 screened T2DM outpatients (age > 18 years) on VMc for at least 
4 weeks prior to enrollment were included in this 24-week, multicenter, observational 
study. Results: Of the 648 patients, 382 (59.0%) were female. The mean (standard devi-
ation-SD-) age was 55.2 (10.2) years, the mean (SD) T2DM duration was 4.8 (5.2) years and 
220 (34.0%) patients had T2DM for more than 5 years. Patients were followed for median 
(inter-quartile range-IQR-) 184.0 (74.0) days at median (IQR) 4.0 (2.0) visits. Median vilda-
gliptin and metformin doses were 100.0 mg and 2000 mg, respectively. HbA1c decreased 
from 7.8% to 7.0% (p< 0.001). A similar reduction in HbA1c from 7.6% to 7.1% was also seen 
in elderly patients (> 65 years, 18.1% of patients) (p< 0.001). The proportion of patients 
with HbA1c ≤ 6.5% increased from 13.3% to 42.7% (p< 0.001) and those with HbA1c ≤ 7.0% 
increased from 26.6% to 65.3% (p< 0.001). Mean fasting plasma glucose (FPG) decreased 
from 153.1 mg/dL to 136.5 mg/dL (p< 0.001), whereas mean post-prandial plasma glucose 
(PPG) decreased from 217.6 mg/dL to 182.1 mg/dL (p< 0.001). Eighty (12.3%) patients expe-
rienced 122 adverse events (AEs) including 3 serious AEs; 2 SAEs were not suspected to 
be related to VMc. AEs were mostly (94.3%) mild or moderate in severity and no action 
was taken for 44.3% of them; 76.2% of AEs resolved during follow-up. cOnclusiOns: 
The results of the GALATA study suggested that VMc significantly decreased HbA1c, FPG 
and PPG, achieved glycemic control targets even in elderly patients and demonstrated 
good overall safety and tolerability in T2DM patients.
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Objectives: Collect randomized clinical evidence on the efficacy and safety of anti-
diabetic agents used in dual or triple therapy or add-on to insulin to provide a qualita-
tive overview of the available evidence and undertake a meta-analysis. MethOds: 
A SLR was conducted in line with NICE guidelines to identify randomised controlled 
trials assessing agents received in combination with metformin (MET), a sulphony-
lurea (SU), MET+SU, MET+pioglitazone, or insulin. Interventions of interest included 
SGLT-2 inhibitors (canagliflozin and dapagliflozin), sulphonylureas, pioglitazone, 
DDP-4 inhibitors, GLP-1 analogues and insulin. Electronic searches were undertaken 
using Medline, Medline-in-process, Embase, and the Cochrane Library and supple-
mented with hand searches. An ad hoc search was conducted to identify the most 
recent data at 104 weeks. Results: A total of 159 clinical trials met inclusion criteria. 
The frequency of studies by background therapy was as follows: MET (38%), mixed 
(trials containing treatment arms with different background therapies; 25%), insulin 
(21%), MET+SU (9%), and SU alone (8%). One study (assessing canagliflozin) featured 
a background of MET+pioglitazone. Studies varied in terms of treatment duration (12 
to 104 weeks), presence and duration of run-in periods (57% studies with run-in, from 
0.7 to 18 weeks), HbA1c eligibility criteria (minimum from 6% to 7%), body mass index 
(BMI; 37 studies focused on overweight and obese patients, two studies focused on 
obese patients) and age for inclusion (from ≥ 18 to ≤ 85 years). cOnclusiOns: The 
outcome of this SLR will serve as input-data in a meta-analysis, to assess relative 
efficacy of T2DM treatments in different background therapy settings.
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tion was built (Tableau 8) to visualize the information to be easily communicated to 
local authorities and clinicians. Results: A middle-sized Finnish municipality with 
74 168 inhabitants (Joensuu) was chosen as a case-example. The estimated num-
ber of diabetic patients was 2267, out of which 1678 had T2D. Within three years 
among patients with T2D, the predicted number of CHD events would be 73 and 
57 for HbA1c levels 6.5% and 8.0%, respectively, resulting total of 16 avoidable CHD 
events. cOnclusiOns: By bringing the understanding of epidemiology and treat-
ment effects to local level, there is a possibility to show the positive outcomes of good 
diabetes care in real practice. This information may be used to help budget holders 
in resource allocation and to motivate authorities, clinicians (and patients) to follow 
the diabetes treatments guidelines.
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Objectives: To obtain information regarding the presence of cardiometabolic risk 
factors among adrenal insufficiency (AI) patients in Italy. To understand treatment 
patterns and goals and to gain consensus regarding how effectively existing therapies 
meet these goals. MethOds: A two-stage Delphi process was conducted with four 
Italian key opinion leaders (KOLs). Each KOL completed an electronic survey eliciting 
information regarding AI management and the prevalence and importance of risk 
factors. To reach a consensus on the key issues, the results were discussed at a face-
to-face meeting. Results: The KOLs agreed that avoiding adrenal crisis is the main 
treatment goal, and that quality of life and avoiding fatigue are most important to 
patients. Patients typically receive 20–30 mg cortisone acetate or hydrocortisone daily 
in 2-3 administrations. A consensus was reached that cardiometabolic risk factors 
are not hallmarks of AI, but are related to its glucocorticoid replacement treatment 
(GC) either due to overtreatment or non-physiological replacement of serum cortisol. 
In agreement with the available evidence in the literature they suggested that the 
increase risk may be associated with the non-physiological cortisol peaks and troughs 
that are characteristic of the existing GC replacement therapies. They established that 
50% of AI patients are over treated, often to minimise the risk of adrenal crisis and all 
patients currently face non-physiological cortisol replacement, given the available 
treatments. GC replacement–related risks included (prevalence in AI in parenthe-
ses): hypertension (10–30%), abdominal obesity (15–35%), dyslipidaemia (33%) and 
metabolic syndrome (30–35%). cOnclusiOns: The prevalence of cardiometabolic 
risk factors is associated with the treatment of AI, not AI itself. Over-treatment and 
non-physiological cortisol replacement may explain cardiometabolic risks. A physi-
ological alternative to existing treatments would be welcomed in Italy.
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Objectives: Type 2 Diabetes mellitus (T2DM) is becoming a major chronic disease 
burden worldwide. Indians are known to have an increased predisposition for diabetes 
which has become an important health concern. The current analysis is aimed to 
systematically review medical literature on T2DM, its prevalence and complications in 
India and also explore the differential risk factors in sub-groups. MethOds: Studies 
are being retrieved from Pubmed, Cochrane and Embase databases using relevant 
search strategies. Search limits are: articles in English, in human adults and published 
since year 2001. Pre-specified inclusion/exclusion criteria will identify study types, 
such as randomized controlled trials (RCTs), observational and retrospective studies 
reporting incidence/prevalence, risk factors and complications of T2DM patients in 
India. Two researchers will independently extract the data and analysis of comparable 
outcomes will be carried out as per appropriate statistics along with critical appraisal 
of the studies. Meta-analysis will be done using RevMan (v5.0) Results: Though 
there have been several studies assessing incidence/prevalence, complications and 
risk factors for T2DM, a systematic review/meta-analysis of the evidence is lacking 
in the Indian scenario. This study aims to provide the much-needed evidence link-
ing incidence/prevalence, complication and risk factors in different groups of T2DM 
patients. This study hopes to demonstrate association of various risk factors with 
disease progression and with complications of T2DM. cOnclusiOns: The prevalence 
of T2DM has been increasing over the years. The data from published studies will 
hopefully answer some of the prevailing variations and trends in prevalence of T2DM 
between different subgroups of T2DM patients and their association with risk factors.
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Objectives: To review lifestyle and genetic factors during pregnancy and early child-
hood in South Asian population living in Europe that may influence later risks of 
insulin resistance, metabolic syndrome, T2DM and CVD MethOds: A systematic 
search, using controlled and free terms (i.e.- metabolic-syndrome, glucose-intol-
erance, diabetes-mellitus, pregnancy, foetal development, life-style, nutrition) was 
conducted in Medline, Centre for Reviews and Dissemination and Cochrane Library 
databases. It was completed by pearling and hand-searching. Two reviewers assessed 
independently the results retrieved in the search, to adopt a decision on inclusion/
exclusion. The quality of included papers was appraised with STROBE checklist for 
than the non-AI population. Since the comparison was unmatched, results should be 
interpreted with caution. Ongoing analysis will include a detailed data assessment, 
with a stronger comparison against matched non-AI populations.
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Objectives: To estimate the cumulative incidence and cost of cardiovascular (CV) 
complications (stroke, acute coronary syndrome (ACS), acute heart failure (AHF) 
and peripheral vascular disease (PVD)) leading to hospitalization in T2D patients 
with a CV complication history in France. MethOds: We conducted an analysis of 
the Program for a Medicalized Information System (PMSI) databases which record 
all hospitalizations occurring in France including rehabilitation care. We identi-
fied all patients with a T2D diagnosis and hospitalized for any reason in 2006-2008 
and selected patients with a documented CV complication history. We analyzed 
those patients as a retrospective cohort followed-up for 3 years from the index 
date (January 1st 2009) and calculated cumulative incidences of new CV complica-
tions. We considered death as a competing event. Mean hospital and rehabilitation 
costs were based on the National Scale of Costs. Results: A total of 1,114,182 T2D 
patients were hospitalized in France in 2006-2008. Among them, 30.5% (n= 339,328) 
had a CV complication history. Mean age was 70.6 (+/-11.1), and 61.9% were males. 
Hypertension, dyslipidemia, renal impairment and obesity were reported in 
80.1%, 45.0%, 33.3% and 29.2% of the patients, respectively. The 3-year cumulative 
incidences for one or more new CV complication were: 3.6% [95%CI:3.5%;3.7%] for 
stroke, 5.6% [95%CI:5.5%;5.7%] for ACS, 6.8% [95%CI:6.7%;6.9%] for AHF and 15.0% 
[95%CI:14.9%;15.1%] for PVD with a mean cost per event of € 5,724, € 5 315, € 4 726, € 4 
766, respectively. 21.8%, 10.5%, 11.4% and 9.5% of patients required rehabilitation 
care for stroke, ACS, AHF and PVD, at an additional mean cost of € 12,000, € 6 233, € 6 
987 and € 9 219 per patient, respectively. cOnclusiOns: CV complications represent 
an important burden for T2D patients and the health system in France. These results 
would be helpful for health technology assessment and for economic evaluation of 
upcoming interventions which reduce CV risk in T2D patients.
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Objectives: While concerning to diabetic treatment, any suboptimum therapy may 
lead to medication error (ME). Objective of study was to report the causes, severity, 
increase in cost of therapy and outcomes of ME in patients undergone treatment for 
diabetes in medicine ward of a community hospital. MethOds: Prospective obser-
vational study (8 months). In-patients with type-II diabetes mellitus were chosen 
randomly and the details were followed till discharge. Results: Incidences of 504 
MEs were observed in 164 out of total patient pool of 230. The notable trends in MEs 
identified were- erroneous prescriptions 101(20.03%), inappropriate dosage-form 
93(18.4%), incorrect-route 63 (12.5%), incident of drug interactions 129 on 55 patients 
(10.09%), failure to monitor lab levels 27(5.30%), failure to adjust doses according to 
lab levels 37(7.14%) and 21(4.16%) cases of incorrect-indications. On severity scale, 
MEs were classified as 143(28.37%) severe, 256(50.79%) moderate and 105(20.8%) mild. 
Predicted error outcome of 164 incidences which were reaches to patient classified 
as- no serious 85(51.8%), moderately serious 61(37.19%), 9(5.3%) life threatening and 
9(5.35%) death (predicted). We observed fair degree of linear correlation between 
increasing age and occurrence of ME 0.99 (rcritical value-0.878). Female sex was found 
to be at higher risk of MEs than male (X2= 6.73, P-value= 0.01). There was a linear 
correlation observed between the polypharmacy and ME 0.95 ( rcriticalvalue-0.44). It 
was observed that, out of total 129 drug interactions identified; only 35(27.13%) were 
moderate, while 72(55.81%) were severe and 22(17.05%) found mild. Significant incre-
ment in the length of stay in hospital and direct drug cost were observed among the 
severe, moderately severe and in mild cases. cOnclusiOns: The observed finding 
of ME defines specific clinical domains and patient subgroups for which aggressive 
efforts needed to reduce MEs. Through information dissemination and education, 
managed health care professionals should play more active role in ME-reduction.
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Objectives: Type 2 diabetes (T2D) and its consequences are largely studied world-
wide. The number of diabetic patients is increasing and thus, a growing number 
of health care resources are needed to cover the treatment of this population. It is 
also known that in spite of the national treatment guidelines, the recommended 
HbA1c level (< 6.5%/48 mmol/mol) is not always achieved. In order to allocate the 
resources effectively, local information concerning epidemiological and demographic 
differences across different jurisdictions must be available. MethOds: A national 
population-based study (Finriski 2007) was used to estimate the prevalence of dia-
betes in different geographical areas. The estimated prevalence rates and number 
of T2D patients were extrapolated to municipal level using demographic data from 
the official statistics. UKPDS risk equation was used to predict the number of cardio-
vascular events with and without proper treatment in each municipality. Local risk 
profile and different HbA1c levels (6.5% (48 mmol/mol) and 8.0% (64 mmol/mol)) were 
used to illustrate the importance of treating patients to target. A map-based applica-
